BALTIMORE, MD--(Marketwired - Jul 16, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that finding preventive measures or products that health-conscious men can routinely use or consume will emerge as a method of fighting prostate cancer. Moreover, such prevention creates a large opportunity and market for companies such as Plandaí Biotechnology, Inc. (
Prostate cancer is a leading cause of death in men. According to the American Cancer Society, in 2013 nearly 240,000 men will be diagnosed with the disease and nearly 30,000 will die from it in the U.S. alone. Plus, one in six men will be diagnosed with prostate cancer at some point in their lives. Finally, prostate cancer is the second leading cause of cancer related death in men, behind only lung cancer.
Carotenoids are substances found in fruits that give them their respective bright colors, like tomatoes and oranges. These nutrients are a key source of vitamin A and lycopene; a substance derived primarily tomatoes, which have been found to be beneficial in prevention of prostate cancer. Data from a University of Illinois-Chicago study in 2010 demonstrated that men who consume a significant amount of lycopene reduced the risk of developing the disease by 35%. Additionally, in a large epidemiologic study by Harvard University, researchers found that men who ate at least 10 servings a week of tomato-based foods reduced their risk for prostate cancer by 45%, while those who had four to seven servings lowered their risk by 20%.
Plandaí Phytofare Carotenoid Complex is a unique product that harnesses the beneficial effects of these nutrients due to the Company's proprietary and advanced extraction process and ability to generate high absorption into the blood stream. In fact, the product will offer one of the highest levels of lycopene found in a dietary supplement. Looking at the Company's line of offerings, we believe that this will be the third product in the Plandai arsenal that will be marketed and sold in 2014. Among other approaches in marketing the Phytofare Carotenoid Complex, Plandaí will target the health conscious consumer seeking prevention of diseases like prostate cancer, which is likely a market reaching the hundreds of millions of dollars annually.
Goldman Small Cap Research articles and reports on Plandai as well as associated disclaimers can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Plandai Biotechnology, Inc. (
- Disease & Medical Conditions
- prostate cancer